Search Within

Larry Norton

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (38)
  2. Journal Article (26)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (64)
  2. Breast Medicine Service (64)
  3. Department of Medicine (64)
  4. GSK Faculty (64)
  5. Human Oncology and Pathogenesis Program (64)
  6. Solid Tumor Oncology Division (64)

More Groups

People
  1. Sarat Chandarlapaty (36)
  2. Jorge Reis-Filho (25)
  3. David Solit (23)
  4. Shanu Modi (21)
  5. Michael Berger (20)
  6. Clifford Hudis (18)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (4)
  4. 2022 (4)
  5. 2021 (3)
  6. 2020 (8)

More Years

Publications
  1. Journal of Clinical Oncology (15)
  2. Cancer Research (10)
  3. Clinical Cancer Research (6)
  4. Laboratory Investigation (4)
  5. npj Breast Cancer (4)
  6. Annals of Oncology (3)

More Publications

Publishers
  1. American Association for Cancer Research (17)
  2. American Society of Clinical Oncology (17)
  3. Nature Publishing Group (12)
  4. Oxford University Press (6)
  5. Nature Research (4)
  6. American Society of Hematology (2)

More Publishers

Results (64)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Modulation of Hsp90 function by ansamycins enhances chemotherapy induced apoptosis in breast cancer cell lines in an RB and schedule dependent manner
    Meeting Abstract

    Munster, P. N.; Basso, A. D.; Solit, D.; Norton, L.; Scher, H.; Rosen, N.
    Proceedings of the American Association for Cancer Research Annual Meeting (2001)

    Fulltext@MSK | Save
  • 17-Allylamino-geldanamycin causes AKT inactivation and enhances the anti-tumor effects of paclitaxel
    Meeting Abstract

    Solit, D. B.; Basso, A. D.; Munster, P. N.; Norton, L.; Scher, H. I.; Rosen, N.
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: The Biology Behind: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters. Clin. Cancer Res., 7: 2155-2158, 2001
    Journal Article

    Munster, P. N.; Basso, A.; Solit, D.; Norton, L.; Rosen, N.
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • 17-allyl-amino-seldanamycin induces HER2 degradation and AKT inactivation in a human breast cancer xenograft model
    Meeting Abstract

    Solit, D.; Munster, P.; Basso, A.; Tong, W.; Agus, D.; Scher, H.; Norton, L.; Rosen, N.
    Clinical Cancer Research (2000)

    Fulltext@MSK | Save